Meet Our Team
tVNS® – currently the only non-invasive vagus nerve stimulation device approved under the European Medical Device Regulation. Experience an evidence-based, transcutaneous, and mobile therapy option for neurological and psychiatric patients.
With its non-invasive approach, patient-friendly treatments, and minimal side effects, tVNS® offers a new horizon of hope and relief for those living with neurological conditions. Embrace a future where each day holds the promise of greater comfort and enhanced quality of life.
Certified Medical Device
tVNS® is the world’s only non-invasive vagus nerve stimulation approved as a Class IIa medical device under the EU-MDR, offering a scientifically validated treatment for conditions related to sympathovagal imbalance.
Non-Invasive Approach
A safe and gentle alternative to surgery and medication, tVNS® stimulates the vagus nerve through the skin, offering a harmonious path to wellbeing with very low side-effects.
Control at Your Fingertips
Use our innovative tVNS® device anywhere and monitor your treatment through our user-friendly app. You have the freedom to tailor your therapy to your lifestyle.
Most Effective Stimulation Site
tVNS® is the only non-invasive stimulation device that stimulates the cymba concha, resulting in 100% vagus nerve innervation (as opposed to e.g. the tragus, which only results in 45% innervation).
A randomized, double-blind crossover study of 20 seizure-free temporal lobe epilepsy patients found that 4 hours of transcutaneous vagus nerve stimulation (tVNS) dampened the natural cortisol decline and reduced salivary flow rate compared to sham stimulation. This suggests modest short-term effects on stress-related biological systems, though subjective stress and tiredness were unchanged.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A 30-subject EEG study found that transcutaneous auricular vagus nerve stimulation (taVNS) modifies functional brain network properties in ways that differ by epilepsy type. Generalized and focal epilepsy groups showed opposite patterns of network reorganization during and after stimulation, suggesting taVNS effects are not uniform across epilepsy types. Local brain network changes were largely diffuse and non-specific.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A crossover study of 15 patients with drug-resistant epilepsy found that neither acute invasive VNS nor taVNS improved verbal memory performance on a word recognition task. However, memory scores improved significantly after 6 weeks of VNS treatment, suggesting sustained, repetitive stimulation at moderate intensity is needed to meaningfully enhance memory function.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A prospective trial of 14 epilepsy patients found that one hour of taVNS produced measurable, often persistent changes in EEG-derived brain network properties, including increased integration, robustness, and stability. Importantly, these network modifications occurred without any negative impact on cognition or behavior, suggesting taVNS may promote a more resilient epileptic brain network.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A multicenter feasibility trial of taVNS in 37 drug-resistant epilepsy patients was terminated early due to poor recruitment and high dropout. Only 59% completed six months and 16% completed the full 18-month follow-up. The findings highlight that patient adherence and device usability are critical barriers to real-world taVNS adoption, independent of clinical efficacy.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A comprehensive review of 30 years of VNS literature found that invasive VNS achieves 50% seizure reduction in roughly 45 to 65% of drug-resistant epilepsy patients, with efficacy peaking around 6 months and continuing to improve for up to 2 years. Non-invasive taVNS shows promise but remains limited by small study sizes, inconsistent protocols, and lack of long-term data.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A retrospective study of 52 post-stroke epilepsy patients found that 4 weeks of taVNS showed no significant improvement in seizure frequency, seizure duration, or quality of life compared to a waiting-list control group. The authors attributed the null findings to a short treatment duration, low stimulation dose, and small sample size.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A double-blind RCT of 76 drug-resistant epilepsy patients comparing 25 Hz taVNS against 1 Hz active control found no statistically significant superiority for the active treatment group overall. However, patients who completed the full 20-week treatment showed a significant 34% seizure reduction, and adherence was high. The authors concluded that larger, longer trials are warranted.
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
A case report of a 17-year-old with longstanding treatment-resistant depression found that 7.5 months of daily home-based taVNS, adjunct to escitalopram, was feasible and well-tolerated, with modest improvements in self-reported and clinician-rated depression scores. The authors note that existing protocols are not yet optimized for adolescents and call for dedicated pediatric research.
tVNS® led to a reduction of depression-specific HAMD score of a minimum of 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks.
A crossover study of 30 MDD patients and 29 healthy controls found that taVNS boosted effort invigoration during the first session in both groups, with gains persisting into a second session rather than requiring repeated acute stimulation. Patients with MDD showed trial-by-trial increases in both invigoration and reward wanting during taVNS, suggesting the stimulation may facilitate motivational learning that could complement existing depression treatments.
tVNS® led to a reduction of depression-specific HAMD score of a minimum of 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks.
A single-arm feasibility study of 20 treatment-resistant depression patients found that 80% achieved the compliance threshold of 4 hours of daily taVNS over 4 weeks. Side effects were mild and mostly local. Significant reductions in depression severity and improvements in cognitive speed were observed, supporting the case for larger randomized trials in this difficult-to-treat population.
tVNS® led to a reduction of depression-specific HAMD score of a minimum of 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks.
A randomized crossover trial of 33 depressed and 30 non-depressed adolescents found that acute taVNS did not improve general emotion recognition accuracy but did alter response inhibition on an emotional Go/NoGo task. Notably, taVNS reduced responses to sad stimuli in depressed adolescents while improving overall recognition in controls, suggesting the stimulation may specifically modulate negative-valence processing in adolescent depression.
tVNS® led to a reduction of depression-specific HAMD score of a minimum of 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks.
A non-blind case series of five adults with Prader-Willi Syndrome found that four hours of daily taVNS over 12 months produced significant reductions in temper outbursts in four of five participants, with improvements emerging around month nine. Halving the stimulation time to two hours reversed gains in most participants, suggesting sustained high-dose stimulation is necessary to maintain therapeutic effects.
Treatment with tVNS® led to a reduction of 50% of the frequency of days with chronic migraines after a treatment period of 12 weeks.
A systematic review and meta-analysis of 14 studies covering 995 patients found that preventive transcutaneous nerve stimulation reduced headache frequency by roughly 3 days per month in both episodic and chronic migraine, with episodic migraine patients also experiencing meaningful reductions in pain severity. The authors concluded that transcutaneous stimulation represents a clinically significant non-pharmacologic migraine prevention option.
Treatment with tVNS® led to a reduction of 50% of the frequency of days with chronic migraines after a treatment period of 12 weeks.
A 12-month case series of five Prader-Willi Syndrome patients found that daily taVNS significantly increased heart rate variability and reduced resting heart rate, both indicating enhanced vagal activity. Higher HRV levels predicted fewer emotional outbursts, suggesting taVNS may improve behavioral regulation by targeting autonomic nervous system dysfunction in this population.
After a treatment period of 12 months, 80% of tVNS® patients recorded a reduction of the mean number of outbursts per day of 50%, compared to the mean number of outbursts per day before treatment.
An ongoing randomized controlled trial (currently recruiting) based at Maastricht University Medical Center testing 8 weeks of taVNS against sham in irritable bowel syndrome patients. Primary outcomes include symptom reduction, quality of life, anxiety, and depression. The study also aims to determine whether a pre-treatment autonomic and brain imaging “neurosignature” can predict who will respond to taVNS.
After a treatment period of 12 months, 80% of tVNS® patients recorded a reduction of the mean number of outbursts per day of 50%, compared to the mean number of outbursts per day before treatment.
A non-blind case series of five adults with Prader-Willi Syndrome found that four hours of daily taVNS over 12 months produced significant reductions in temper outbursts in four of five participants, with improvements emerging around month nine. Halving the stimulation time to two hours reversed gains in most participants, suggesting sustained high-dose stimulation is necessary to maintain therapeutic effects.
After a treatment period of 12 months, 80% of tVNS® patients recorded a reduction of the mean number of outbursts per day of 50%, compared to the mean number of outbursts per day before treatment.
tVNS® has already been featured in numerous renowned national and international health, science, and innovation media outlets for its evidence-based approach to non-invasive vagus nerve stimulation. The coverage underscores the growing medical and scientific interest in transcutaneous vagus nerve stimulation and the importance of clinically sound technology certified under the European Medical Device Regulation (MDR) in modern neuromodulation.
Click the publications logo that you would like to see, or scroll below and click on the article you would like to read.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Worldwide, more and more patients, researchers, and physicians are having positive experiences with tVNS®. These insights help us continuously improve tVNS® therapy and apply it in a targeted way.
“Epilepsy had me always bracing for the next episode. Since integrating tVNS®, there’s been a marked change in the regularity of my seizures. It’s more than relief; it’s empowerment.”
“The weight of depression had become an all-too-familiar companion. While the journey continues, tVNS® has offered a supportive hand, complementing my therapies and blessing me with brighter days.”
“It’s wonderful that with tVNS® I have found a treatment option for my Epilepsy that makes me feel better without needing surgery and worrying about side-effects.”
“Epilepsy had me always bracing for the next episode. Since integrating tVNS®, there’s been a marked change in the regularity of my seizures. It’s more than relief; it’s empowerment.”
“Epilepsy had me always bracing for the next episode. Since integrating tVNS®, there’s been a marked change in the regularity of my seizures. It’s more than relief; it’s empowerment.”
Navigating treatment options can be overwhelming, especially when conventional therapies fall short. tVNS® offers a non-invasive approach by gently stimulating the vagus nerve through the ear, supporting balance within the nervous system without surgery or medication-related side effects. Approved as a Class IIa medical device under the EU-MDR, it combines safety, simplicity, and scientific rigor.
With over 20 years of experience, we are pioneers in non-invasive vagus nerve stimulation. Backed by robust clinical research and developed and manufactured in Germany, our devices are trusted worldwide by clinicians and researchers for their precision, reliability, and high quality standards.
What Makes Our Device Special?
Our tVNS® device is the only non-invasive VNS device that is approved as a medical device under the EU-MDR.
of experience pioneering the non-invasive vagus nerve stimulation.
of the vagus nerve is achieved via stimulation of the cymba concha.
of German precision engineering, trusted by researchers and clinicians worldwide.
Transcutaneous aricular vagus nerve stimulation with the tVNS® E is a systemic therapy. Here, sensory fibers of the vagus nerve in the Cymba Conchae of the auricle (outer ear) are addressed, which send the signal further to the brainstem and the cerebral cortex. From there, the signal travels back into the body’s trunk to almost all organs.
Stimulation of the afferent branches of the vagus nerve in the ear can therefore influence all major organ systems and thus many different diseases and pathophysiologies. Numerous research projects are currently underway worldwide for conditions such as stroke, ME/CFS, Sleep Disorders, Parkinson’s, Chronic Inflammatory Bowel Diseases or Atrial Fibrillation.
In this unboxing video, we walk you through the tVNS® device step by step, showing exactly what’s included and how to get started. You’ll see how to set up the device, place the electrode correctly, and begin your first session with confidence. Designed to be intuitive and easy to use at home, this guide helps ensure a smooth start and supports safe, comfortable integration of tVNS® into your daily routine.
